Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/2/?d=1Neue Studien: Europe PMCdeSeverity of Psoriasis in Tunisia: Cross-Sectional Results From the National PsoTReg Registry.https://www.psoriasis-news.de/articles.html/1_articles/severity-of-psoriasis-in-tunisia-cross-sectional-results-from-the-national-psotreg-registry-r678/BackgroundPsoriasis is a chronic, inflammatory disease affecting up to 5% of the population. It significantly impacts patients' quality of life. In Africa, data on disease severity remain limited. The aim of this study was to evaluate the prevalence of severe psoriasis among Tunisian patients and to identify factors associated with disease severity and impairment of quality of life.

Methods

A cross-sectional study was conducted using data from the Tunisian National Psoriasis registry (PsoTreg) (ClinicalTrials.gov ID: NCT05258838). A total of 1100 patients with psoriasis were included between July 12, 2022, and November 15, 2024. Disease severity and quality-of-life impairment were assessed using the Simplified Psoriasis Index (SPI). Demographic, clinical, and lifestyle data were analyzed to identify factors associated with disease severity and quality-of-life impairment.

Results

Moderate-to-severe psoriasis affected 31.9% of patients, with 38.3% experiencing quality-of-life impairment. Multivariate analysis confirmed male gender (odds ratio [OR]: 2.057), psoriatic arthritis (OR: 1.693), and substance use (alcohol OR: 2.759; smoking OR: 1.609) as independent severity predictors. There were gender-specific patterns, with smoking significantly associated with severity in men and obesity with quality-of-life impairment in women.

Conclusions

This study, the first multicenter psoriasis registry in North Africa, highlighted the prevalence of moderate-to-severe psoriasis (31.9%). It emphasized a high proportion of patients with quality-of-life impairment (38.3%). Psoriasis severity was associated with smoking in men and obesity in women. These findings suggest a need for gender-tailored lifestyle interventions prioritizing mental health screening in the management of psoriasis patients.

Weiterlesen

]]>678Mon, 27 Jul 2026 11:28:11 +0000Exosome-Loaded Zinc Sulfide Nanoparticles Therapy for Psoriasis: Immune Regulation and Skin Repair by Targeting IL-23/IL-17A-NF-κB Pathway.https://www.psoriasis-news.de/articles.html/1_articles/exosome-loaded-zinc-sulfide-nanoparticles-therapy-for-psoriasis-immune-regulation-and-skin-repair-by-targeting-il-23il-17a-nf-%CE%BAb-pathway-r677/In vivo, EXO-ZnS NPs significantly attenuated psoriatic symptoms, and Severity Index scores, reduced inflammatory mediators (IL-23, IL-17a, TNF-α, MCP-1, NLRP3), mitigated oxidative stress, downregulated proliferative markers (Ki-67, MMP-9), and inhibited VEGF-mediated angiogenesis. collectively restored epidermal structure and improved skin architecture. EXO-ZnS NPs synergistically combine the regenerative and immunomodulatory effects of exosomes with the intrinsic anti-inflammatory and antioxidant activities of ZnS NPs, offering a novel promising, dual-action therapeutic platform for effective and sustained psoriasis management.

Weiterlesen

]]>677Mon, 27 Jul 2026 11:28:11 +0000[Elephantine Psoriasis. A case report].https://www.psoriasis-news.de/articles.html/1_articles/elephantine-psoriasis-a-case-report-r676/BackgroundHyperkeratotic psoriasis is a rare variant that includes forms such as elephantiasis, considered the rarest. It is characterized by thick, persistent plaques, resembling elephant skin, located mainly on the extremities and buttocks. Early detection and appropriate treatment, including systemic therapies, are essential for its management.

Clinical case

A 58-year-old male patient presented in 2018 with dermatosis on his forehead, right elbow, and the backs of both hands. He was initially diagnosed with seborrheic dermatitis and chronic lichen simplex and received multiple topical therapies without improvement. In 2024, he developed new, disseminated lesions on his elbows, hands, and both legs, characterized by hyperkeratotic plaques and excoriations. A biopsy confirmed the diagnosis of elephantiasis variant hyperkeratotic psoriasis. Treatment with ustekinumab was initiated, resulting in significant improvement of the lesions.

Conclusions

Elephantine psoriasis is a rare and difficult-to-treat variant, with few reported cases, which hinders the standardization of its management. Biologic therapies represent an effective alternative for improving prognosis, reducing complications, and preventing progression to other associated pathologies. Disseminating these cases is essential to expanding knowledge of this variant and optimizing available therapeutic options, for the benefit of patients.

Weiterlesen

]]>676Mon, 27 Jul 2026 11:28:11 +0000Psoriasis-risk SNP rs610604 reveals nuclear IKKα-TNFAIP3 repressor axis driving autoinflammatory circuits.https://www.psoriasis-news.de/articles.html/1_articles/psoriasis-risk-snp-rs610604-reveals-nuclear-ikk%CE%B1-tnfaip3-repressor-axis-driving-autoinflammatory-circuits-r675/Weiterlesen

]]>675Mon, 27 Jul 2026 11:28:11 +0000Xiegan Liangxue Jiedu Decoction ameliorates psychiatric comorbidities in psoriasis via regulation of sphingolipid metabolism.https://www.psoriasis-news.de/articles.html/1_articles/xiegan-liangxue-jiedu-decoction-ameliorates-psychiatric-comorbidities-in-psoriasis-via-regulation-of-sphingolipid-metabolism-r674/Ethnopharmacological relevanceXiegan-Liangxue-Jiedu decoction (XLJD) is an ethnopharmacological empirical prescription inherited from Gu's Surgery, a national intangible cultural heritage of Chinese ethnomedicine. Developed based on the classic TCM theory of Liver governing emotion, XLJD has been clinically used for centuries to treat psoriasis (PsO) via the principle of the TCM principle of "treating PsO from the Liver perspective", and has shown favorable efficacy in alleviating psychiatric comorbidities in psoriasis (PCP) by soothing the Liver and relieving emotional discomfort.

Aim of the study

To determine the therapeutic efficacy of XLJD and its potential mechanisms of action in PCP mice, and to reveal the modern pharmacological mechanism of the TCM theory of Liver governing emotion in the treatment of PCP.

Materials and methods

Mass spectrometry were used to elucidate XLJD's phytochemical profile and blood-absorbed components. The murine PCP model was established by exposure to CUMS and imiquimod. The efficacy of treating PsO was evaluated using PASI, HE staining, lymphocyte proliferation levels, cytokine levels, etc. Mental disorders were evaluated using the open field, elevated plus maze, and tail suspension tests. RNA-seq was performed to detect transcriptional changes in skin tissues, while lipidomics was applied to analyze serum lipids. Key genes and protein were validated using qPCR and Western-blotting, respectively. Acid sphingomyelinase (ASM) and M1/M2 microglia in the hippocampus were determined via immunofluorescence staining.

Results

Among the 142 compounds identified in XLJD, 21 were detected in the blood. XLJD significantly alleviated the severity of PsO-related indicators in PCP mice while ameliorating behavioral abnormalities and mitigating HPA axis hyperactivity. XLJD downregulated the transcription of genes involved in lipid metabolism and ameliorated abnormal sphingolipid (SP) metabolism. It inhibited lesions mediated by sphingosine-1-phosphate signaling in lesioned skin. In the hippocampus, XLJD reduced the proportion of M1 microglia and exerted potential neuroprotective effects by inhibiting ASM expression and activity.

Conclusions

Based on the TCM theory of Liver governing emotion, XLJD alleviated PsO severity and improved associated mental dysfunctions concomitantly in PCP mice by regulating SP metabolism. This study verifies the scientific connotation of the ethnopharmacological principle of treating PsO from the Liver perspective and provides a new ethnopharmacological strategy for the clinical management of PCP.

Weiterlesen

]]>674Mon, 27 Jul 2026 11:28:11 +0000Blood ACE Activity Is Significantly Lowered in Psoriasis Compared to Atopic Dermatitis: A Small Pilot Study in Young Males.https://www.psoriasis-news.de/articles.html/1_articles/blood-ace-activity-is-significantly-lowered-in-psoriasis-compared-to-atopic-dermatitis-a-small-pilot-study-in-young-males-r673/PurposeEmerging evidence suggests the involvement of the renin-angiotensin system (RAS) in the pathogenesis and progression of autoimmune dermatological diseases. In a small exploratory study, we investigated angiotensin-converting enzyme (ACE) activity in blood obtained from male probands with psoriasis vulgaris (n = 4) and atopic dermatitis (AD, n = 5).

Methods

The degradation capacity of dabsylated synthetic bradykinin (DBK) with and without inhibition was determined using a thin-layer chromatography (TLC)-based neuropeptide reporter assay.

Results

We observed a significantly reduced capacity for cleavage of DBK in psoriasis patients compared with that in AD patients and controls. In patient samples, the variation in the measured values was generally greater than that in healthy controls. We could not confirm the increased ACE activity in the circulation in psoriasis patients reported by others, likely because of different study designs and detection methods. We did not include samples of female patients and focused on younger men to avoid hormonal effects and minimize age-related factors.

Conclusion

This preliminary study of the hypothesis-generating nature lacks power, but it certainly adds a question to the current view of the role of ACE in psoriasis. Treatments targeting specific components of the RAS could ameliorate inflammatory responses; thus, research in this area is becoming increasingly important.

Weiterlesen

]]>673Mon, 27 Jul 2026 11:28:11 +0000Sugary Drinks and High-Fat Foods are Associated with Poor Treatment Response in Psoriasis: A Prospective Study in Shanghai.https://www.psoriasis-news.de/articles.html/1_articles/sugary-drinks-and-high-fat-foods-are-associated-with-poor-treatment-response-in-psoriasis-a-prospective-study-in-shanghai-r672/PurposeWhile dietary factors are known to be associated with the development and progression of psoriasis, their effect on treatment efficacy remains unclear. Therefore, this study aimed to elucidate the influence of tea consumption, sugar drinks, and high-fat foods on the treatment response in psoriasis.

Patients and methods

We undertook a prospective cohort study comprising 559 patients with psoriasis from Shanghai Skin Disease Hospital between 2022 and 2024. Data on demographics, lifestyle (including tea, sugary drinks, and high-fat food consumption), and disease severity (PASI, BSA, PGA) were collected via structured questionnaires at baseline, week 4, and week 8. The primary endpoints were the proportions of patients achieving PASI 50 responses at week 8. Multivariable logistic regression was used to estimate odds ratios with 95% confidence intervals, adjusting for age, sex, BMI, smoking, alcohol, and treatment regimen. Data were analyzed using SAS 9.4 software.

Results

In the psoriasis cohort (mean age 48.5 years; 73.2% male), 37.1% and 68.7% of patients consumed sugar drinks and high-fat foods ≥2 times/week, respectively. Frequent sugar drinks consumption (≥4 times/week) was independently associated with significantly reduced odds of achieving PASI 50 (adjusted OR=0.24, 95% CI: 0.08-0.75) and PASI 75 (adjusted OR=0.27, 95% CI: 0.07-1.00) at week 8. Moderate intake of high-fat foods (2-3 times/week) showed an inverse, borderline significant association with PASI 50 at week 4 (adjusted OR=0.68, 95% CI: 0.45-1.00). Tea consumption showed a non-significant association with treatment response (e.g, week 8 PASI 50 adjusted OR=1.44, 95% CI: 0.88-2.35), warranting further investigation in larger cohorts.

Conclusion

This study demonstrates that high consumption of sugar drinks and high-fat foods is associated with suboptimal treatment response in psoriasis. Tea consumption was not significantly associated with treatment outcomes, although further investigation with larger cohorts may be warranted. These findings highlight the importance of integrating dietary assessment and counseling into comprehensive psoriasis management.

Weiterlesen

]]>672Mon, 27 Jul 2026 11:28:11 +0000The impact of Langerhans cells on Th17/Treg balance in psoriasis lesions.https://www.psoriasis-news.de/articles.html/1_articles/the-impact-of-langerhans-cells-on-th17treg-balance-in-psoriasis-lesions-r671/BackgroundLangerhans cells (LCs) play a crucial role in sensing and processing stimuli from the skin and the external environment. They are implicated in various skin disorders, acting either as pro-inflammatory agents or as regulatory elements. However, the exact function of LCs in the pathogenesis of psoriasis remains unclear. Psoriasis is characterized by a significant Th17/Treg immune imbalance. To elucidate the independent effect of Treg dysfunction on psoriatic inflammation, we established a Treg-inhibited psoriasis group using the Foxp3 inhibitor CMD178, in conjunction with LC depletion models to investigate the LC-Th17/Treg regulatory axis METHODS: Psoriasis models were established through the topical application of IMQ. Female C57BL/6 N mice were divided into three groups: control, IMQ-induced psoriasis, and Treg-depleted psoriasis. LCswere depleted using diphtheria toxin in Langerin-DTR mice, while Tregs were inhibited by CMD178. Inflammation was assessed through measurements of ear thickness, histopathology, apoptosis, and cytokine production. Additionally, RT-qPCR was utilized to detect the expression of S100A7, S100A8, and MMP2. Flow cytometry was employed to analyze the functional status of lymphocytes and T cell phenotypes.

Results

IMQ-induced psoriasis-like lesions exhibit activated LCs, an increase in Th17 cells, a decrease in Tregs, elevated levels of IL-17A and IL-22, and reduced levels of TGF-β and PD-L1. Depletion of LCs alleviated the lesions and restored the Th17/Treg balance, whereas depletion of Tregs exacerbated the inflammation.

Conclusion

LCs play a central regulatory role in the psoriatic skin environment by influencing the Th17/Treg.

Weiterlesen

]]>671Mon, 27 Jul 2026 11:28:11 +0000<![CDATA[Dihydrotanshinone l alleviates psoriasis-like skin lesion <i>via</i> suppressing STAT3 signaling and DCs-Th17 responses.]]>https://www.psoriasis-news.de/articles.html/1_articles/dihydrotanshinone-l-alleviates-psoriasis-like-skin-lesion-ltigtvialtigt-suppressing-stat3-signaling-and-dcs-th17-responses-r670/Weiterlesen

]]>670Mon, 27 Jul 2026 11:28:11 +0000scSAID: A Comprehensive Cross-Species Single-Cell Skin Atlas Reveals Species-Specific Responses to Psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/scsaid-a-comprehensive-cross-species-single-cell-skin-atlas-reveals-species-specific-responses-to-psoriasis-r669/Weiterlesen

]]>669Mon, 27 Jul 2026 11:28:11 +0000Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.https://www.psoriasis-news.de/articles.html/1_articles/efficacy-and-drug-survival-after-transitioning-to-il-17-inhibitors-in-patients-with-psoriasis-who-did-not-respond-to-il-23-inhibitors-analysis-from-the-biorep-registry-r668/IntroductionSwitching biologics for psoriasis is common; however, data on switching to alternative treatments after failure of IL-23 inhibitors are limited.

Methods

A retrospective analysis was conducted to extract efficacy and drug survival data from the BIOREP registry from January 2015 to June 2025. The analysis included all patients with psoriasis who were switched from an IL-23 inhibitor to an IL-17 inhibitor during this period and had at least one follow-up visit recorded.

Results

A total of 102 patients were switched from an IL-23 inhibitor to an IL-17 inhibitor, with 92 (90.2%) of these switches occurring due to insufficient efficacy. In these 92 patients, PASI-75 was achieved in 82.6% after 3 months and in 73.5% after 12 months. Absolute PASI ≤ 1 was achieved by 66.3% of patients after 3 months and 52.9% after 12 months. Patients treated with bimekizumab had the highest probability of meeting both efficacy parameters, particularly an absolute PASI ≤ 1 after 3 months. The overall survival probability was 79.5% after 12 months and 68.1% after 24 months.

Conclusion

For patients with an inadequate response to IL-23 inhibitors, switching to IL-17 inhibitors offers adequate efficacy in reaching current therapeutic goals during the first year of treatment.

Weiterlesen

]]>668Mon, 13 Jul 2026 15:14:22 +0000Can Systemic Treatment for Childhood Psoriasis Be Stopped in Cases of Remission? Data From the ACMe Cohort.https://www.psoriasis-news.de/articles.html/1_articles/can-systemic-treatment-for-childhood-psoriasis-be-stopped-in-cases-of-remission-data-from-the-acme-cohort-r667/BackgroundIn childhood, moderate-to-severe psoriasis often requires systemic treatments such as acitretin, methotrexate, or cyclosporine. This study aimed to explore the feasibility of discontinuing systemic therapy in pediatric patients who achieve remission when receiving these treatments and to identify predictors of sustained remission.

Methods

The ACMe cohort study was a retrospective, multicenter, international, real-world study involving children and adolescents with moderate-to-severe psoriasis treated with acitretin, methotrexate, or cyclosporine. Patients who achieved remission and stopped their systemic treatment were monitored for up to 6 months to evaluate the need for further systemic treatment.

Results

Of the 433 patients analyzed, 79 (18.2%) discontinued systemic treatment due to remission. Of these, 70 (88.6%) remained off systemic treatment for at least 6 months. Factors predictive of discontinuation due to remission included younger age (9.0 ± 3.5 vs. 10.5 ± 4.1 years, p < 0.001); lower baseline psoriasis severity (PGA: 3.0 ± 0.7 vs. 3.3 ± 0.8; and PASI: 9.3 ± 4.8 vs. 11.1 ± 6.8, p < 0.04); and the presence of non-palmoplantar forms of psoriasis (palmoplantar psoriasis: 5 (6.3%) vs. 58 (16.4%), p = 0.02). No factors were identified that predicted sustained remission at 6 months.

Conclusions

These promising results suggest that systemic treatment discontinuation during clinical remission is feasible for pediatric patients with moderate-to-severe psoriasis and is associated with a low risk of early relapse. Prospective studies with long-term follow-up are needed to confirm the durability of remission and to better define criteria for selecting candidates for treatment discontinuation.

Weiterlesen

]]>667Mon, 13 Jul 2026 15:14:22 +0000Sámi psoriatic arthritis patients in northern Norway receive less conventional synthetic disease-modifying anti-rheumatic drug treatment and have more arthritis, axial symptoms, and joint damage.https://www.psoriasis-news.de/articles.html/1_articles/s%C3%A1mi-psoriatic-arthritis-patients-in-northern-norway-receive-less-conventional-synthetic-disease-modifying-anti-rheumatic-drug-treatment-and-have-more-arthritis-axial-symptoms-and-joint-damage-r666/ObjectivesTo compare Sámi and non-Sámi patients with psoriatic arthritis (PsA) and evaluate potential differences in treatment and joint damage.

Method

A total of 424 adult PsA patients meeting the ClASsification for Psoriatic ARthritis (CASPAR) criteria were recruited from the Norwegian Arthritis Registry and hospitals in northern Norway. A questionnaire from the SAMINOR (a study in regions with Sámi and Norwegian populations) was used to identify Sámi and non-Sámi patients. Demographic and clinical characteristics, joint damage, and disease-modifying anti-rheumatic drug treatment data were compared between the groups. Binary logistic regression was used to adjust for age and gender differences.

Results

Sixty Sámi and 364 non-Sámi patients were identified, and the groups were comparable in demographic characteristics and disease activity measurements. Sámi patients experienced more joint damage than non-Sámi patients (42% vs 26%, p = 0.010), and the highest rate was observed among Sámi men (p = 0.005). Sámi patients also had a higher prevalence of arthritis and axial involvement (92% vs 76%, p = 0.007 vs 32% vs 20%, p = 0.033). In addition, Sámi men showed significant underutilization of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) (83% vs 92%, p = 0.031), particularly methotrexate (68% vs 90%, p = 0.002).

Conclusion

Sámi PsA patients show higher rates of axial involvement, arthritis, and joint damage than their non-Sámi peers. Furthermore, Sámi patients demonstrate underutilization of csDMARDs. These findings underscore the importance of implementing culturally adapted healthcare strategies to improve treatment outcomes for Sámi patients with PsA.

Weiterlesen

]]>666Mon, 06 Jul 2026 17:19:47 +0000Comparative Transcriptomics Reveals SKH-1 Mice as a Valuable Model for Psoriasis Pathogenesis and Recurrence Studies.https://www.psoriasis-news.de/articles.html/1_articles/comparative-transcriptomics-reveals-skh-1-mice-as-a-valuable-model-for-psoriasis-pathogenesis-and-recurrence-studies-r665/Weiterlesen

]]>665Mon, 06 Jul 2026 17:19:47 +0000TCN2 Drives Psoriasis-Like Inflammation and Keratinocyte Hyperproliferation, Correlating With IL-1β and STAT3 Activation.https://www.psoriasis-news.de/articles.html/1_articles/tcn2-drives-psoriasis-like-inflammation-and-keratinocyte-hyperproliferation-correlating-with-il-1%CE%B2-and-stat3-activation-r664/Weiterlesen

]]>664Mon, 06 Jul 2026 17:19:47 +0000Uncovering a Dual Th17/Type 2 Transcriptomic Endotype in Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/uncovering-a-dual-th17type-2-transcriptomic-endotype-in-psoriasis-r663/BackgroundThe IL-23/Th17 axis is the cornerstone of psoriasis pathogenesis, but molecular heterogeneity across different ethnicities remains poorly defined.

Objective

To comprehensively define the immunological and pathogenic transcriptomic profiles of a Taiwanese psoriasis cohort.

Methods

Lesional skin (LS) and non-lesional skin (NL) biopsies from 11 patients with chronic plaque psoriasis and normal skin (N) from 9 healthy controls were analyzed via bulk RNA-sequencing. Differential gene expression (DEG), pathway enrichment (GSEA), and clinical correlations (PASI score) were performed. Serum levels of cytokines were validated via ELISA from all 50 psoriasis patients and 9 healthy controls.

Results

Analysis identified 4,694 DEGs in LS vs. N. We confirmed robust Th17 upregulation (IL-17A/C, IL-23A). Unanticipatedly, a profound dual immune dysregulation was identified, involving significant upregulation of Type 2 (Th2) signatures (IL-4R, CCL17, TSLP). The IL-36 family was the most highly activated cytokine axis (IL-36G log2FCH=5.5). Barrier function genes (KRT77, GJB4) were significantly downregulated. Correlation analysis identified IL-36RN and the combination of AREG/CDSN (r ≈ -0.9, p=0.002) as potential severity biomarkers.

Limitations

The small sample size and focus on a single ethnic group. Transcriptomic findings represent associations rather than mechanistic evidence of pathogenesis.

Conclusion

Taiwanese psoriasis is characterized by a dual Th17/Type 2 endotype and extreme IL-36 activation. This molecular landscape underscores the need for stratified therapeutic strategies in Taiwanese populations.

Weiterlesen

]]>663Mon, 06 Jul 2026 17:19:47 +0000A Systematic Literature Review on Methotrexate Hepatotoxicity in Psoriasis Management: Preconceived Notion or Real Threat?https://www.psoriasis-news.de/articles.html/1_articles/a-systematic-literature-review-on-methotrexate-hepatotoxicity-in-psoriasis-management-preconceived-notion-or-real-threat-r662/Weiterlesen

]]>662Mon, 06 Jul 2026 17:19:47 +0000Personalized Medicine in Psoriasis - A Long Road Ahead?https://www.psoriasis-news.de/articles.html/1_articles/personalized-medicine-in-psoriasis-a-long-road-ahead-r661/Weiterlesen

]]>661Mon, 06 Jul 2026 17:19:47 +0000Multidimensional clinical psychological and quality of life benefits of cyclosporine a therapy in patients with moderate-to-severe plaque psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/multidimensional-clinical-psychological-and-quality-of-life-benefits-of-cyclosporine-a-therapy-in-patients-with-moderate-to-severe-plaque-psoriasis-r660/Weiterlesen

]]>660Mon, 06 Jul 2026 17:19:47 +0000Pediatric psoriasis: from immunogenetics to targeted therapies.https://www.psoriasis-news.de/articles.html/1_articles/pediatric-psoriasis-from-immunogenetics-to-targeted-therapies-r659/BackgroundPediatric psoriasis may result in significant cumulative life course impairment, and there is comparatively less evidence available than for adult psoriasis.

Objective

The aim of this study is to provide an update on the management of pediatric psoriasis, integrating recent immunogenetic and therapeutic advances. It highlights challenges, including clinical heterogeneity, complex differential diagnosis, and limited treatment options, especially in Brazil.

Methods

A narrative review was conducted, including studies published in English, Portuguese, and Spanish between 2009 and 2025, retrieved from the United States National Library of Medicine (PubMed), Cochrane Library, and Scientific Electronic Library Online (SciELO). The following descriptors were used: "psoriasis", "child health", "pediatrics", "therapeutics", "comorbidity", and "T-lymphocyte antigen differentiation".

Results

Pediatric psoriasis most commonly presents as chronic plaque. Differential diagnoses are broad and include atopic dermatitis and autoimmune diseases. Data about comorbidities, particularly cardiovascular risk, are controversial. Although severe cases are less frequent, they are associated with a substantial impact on quality of life. Conventional therapies include topical corticosteroids, phototherapy, and non-targeted systemic agents such as acitretin, methotrexate, and cyclosporine. Biologic therapies have been approved for pediatric use and demonstrate safety profiles and superior efficacy compared to conventional treatments.

Study limitations

Scarcity of pediatric psoriasis guidelines.

Conclusions

Despite advances in understanding adult psoriasis, evidence in pediatric populations remains limited, especially in Brazil. Expanding knowledge in pediatric psoriasis is essential to improve diagnosis, optimize treatment strategies, and increase access to innovative therapies, thereby reducing inflammatory burden and cumulative life course impairment.

Weiterlesen

]]>659Mon, 06 Jul 2026 17:19:47 +0000Identification and experimental validation of biomarkers associated with T cell infiltration in psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/identification-and-experimental-validation-of-biomarkers-associated-with-t-cell-infiltration-in-psoriasis-r658/BackgroundPsoriasis represents a prevalent long-term inflammatory skin condition marked by the dysregulation of immune responses. T cells are integral to the pathogenesis of psoriasis. This study conducted a comprehensive analysis to recognize biomarkers associated with T cell infiltration in psoriasis and to elucidate their underlying molecular mechanisms.

Results

Three biomarkers (AKR1B10, C10orf99, and CKS2) demonstrated high sensitivity and specificity in receiver operating characteristic (ROC) curve, and the reliability of the developed nomogram diagnostic model was observed. In addition, gene set enrichment analysis (GSEA) revealed notable enrichment of the biomarkers in the NOD-like receptor signaling pathway and focal adhesion. Immune infiltration analysis indicated elevated levels of activated B cells and CD8 T cells in psoriasis samples, with the biomarkers showing meaningful correlations with the majority of immune cell infiltration statuses. Importantly, preliminary reverse transcription quantitative PCR (RT-qPCR) validation showed increased expression of AKR1B10, C10orf99, and CKS2 in psoriasis tissues, confirmed higher expression of AKR1B10, C10orf99, and CKS2 in psoriasis patients.

Conclusion

AKR1B10, C10orf99, and CKS2 may serve as candidate molecules for future mechanistic studies and provide potential diagnostic biomarkers for further investigation of psoriasis-related immune regulation.

Weiterlesen

]]>658Mon, 06 Jul 2026 17:19:47 +0000Early Response to Calcipotriol and Betamethasone Dipropionate PAD-Cream at Week 4 in Patients with Mild-to-Moderate Plaque Psoriasis: A Post-Hoc Pooled Analysis of Two Phase III Trials.https://www.psoriasis-news.de/articles.html/1_articles/early-response-to-calcipotriol-and-betamethasone-dipropionate-pad-cream-at-week%C2%A04-in-patients-with-mild-to-moderate-plaque-psoriasis-a-post-hoc-pooled-analysis-of-two-phase%C2%A0iii-trials-r657/IntroductionTopical therapy plays an essential role in psoriasis management. However, lack of rapid improvement may negatively impact adherence. The calcipotriol and betamethasone dipropionate (CAL/BDP) cream based on polyaphron dispersion (PAD) technology has demonstrated high efficacy, favorable safety, and convenience compared with CAL/BDP gel in phase III trials. This post-hoc analysis aims to assess early treatment response to CAL/BDP PAD-cream at Week (W) 4.

Methods

This was a post-hoc pooled analysis of adults with mild-to-moderate psoriasis from two multicenter, investigator-blind, phase III trials (MC2-01-C2 and MC2-01-C7). Patients were randomized 3:1:3 to CAL/BDP PAD-cream (N = 551), PAD-cream vehicle (N = 178), or CAL/BDP gel (N = 542) once daily for 8 weeks. Physician's Global Assessment (PGA) and Subject's Global Assessment (SGA) were assessed at W1 and W4. At W4, early responders were defined as patients achieving PGA controlled disease (i.e., any improvement from baseline to a PGA score of 0-1), while PGA success was defined as a PGA score of 0-1 combined with a minimum 2-point improvement from baseline. SGA controlled disease and SGA success were also assessed. Comparisons between groups were performed by logistic regression models using multiple imputation. Rates of PGA/SGA concordance were assessed by simple percent agreement.

Results

At W4, CAL/BDP PAD-cream was associated with a significantly higher proportion of patients achieving early response compared with CAL/BDP gel (32.1% vs 21.4%, P < 0.0001). Differences were already significant at W1 (7.8% vs 4.8%, P = 0.0410). PGA success at W4 was also higher with CAL/BDP PAD-cream than with CAL/BDP gel (23.6% vs 14.8%, P < 0.0001). Rates of SGA controlled disease and success were also statistically significantly higher for CAL/BDP PAD-cream at W4. Concordance between PGA/SGA assessments at W4 was observed in 65.5% (controlled disease) and 69.5% (success) of patients treated with CAL/BDP PAD-cream.

Conclusion

CAL/BDP PAD-cream was associated with significantly higher early response rates at W4 than CAL/BDP gel, suggesting earlier clinical improvements.

Weiterlesen

]]>657Fri, 03 Jul 2026 07:03:51 +0000Modified Delphi Consensus Recommendations for the Management of Psoriasis in Asia-Pacific.https://www.psoriasis-news.de/articles.html/1_articles/modified-delphi-consensus-recommendations-for-the-management-of-psoriasis-in-asia-pacific-r656/IntroductionPsoriasis imposes a substantial clinical and quality-of-life burden across the Asia-Pacific (APAC) region. Despite advances in systemic therapies, variability in disease severity classification, assessment tools, and treatment escalation criteria continues to contribute to undertreatment and delayed access to effective care.

Methods

A modified Delphi panel was conducted to develop APAC-contextualised consensus recommendations for psoriasis management. Statements were generated from a literature review and refined through Steering Committee interviews and review. The steering committee (n = 6) and Delphi panellists (n = 12) was comprised of dermatology experts from six APAC markets (Australia, China, Japan, South Korea, Malaysia, Taiwan). Consensus was generated through two structured online voting rounds involving all panellists, followed by a moderated consensus meeting, involving only the steering committee, to deliberate on any remaining non-consensus items. Consensus was defined a priori as ≥ 75% agreement among panellists.

Results

In rounds 1 and 2, 92/130 (71%) and 17/24 (71%) statements achieved consensus, respectively. Eight statements were discussed during the steering committee meeting, during which consensus was reached on all eight. In total, 121 statements achieved formal consensus, which includes an additional 4 non-consensus statements from round 1 that were retained in the final recommendations based on steering committee determination of clinical relevance. Recommendations focused on severity classification and assessment thresholds, treatment goals and response criteria, and systemic therapy eligibility and escalation.

Conclusion

These Delphi-derived recommendations provide a practical, patient-centred framework to standardise psoriasis assessment and guide timely treatment escalation in APAC. Adoption may reduce variability in care, support equitable access to appropriate systemic therapies, and improve outcomes across diverse APAC health systems.

Weiterlesen

]]>656Fri, 03 Jul 2026 07:03:51 +0000Topical ronomilast alone or combined with clobetasol ameliorates imiquimod-induced psoriasis in mice.https://www.psoriasis-news.de/articles.html/1_articles/topical-ronomilast-alone-or-combined-with-clobetasol-ameliorates-imiquimod-induced-psoriasis-in-mice-r655/Weiterlesen

]]>655Fri, 03 Jul 2026 07:03:51 +0000Integrated Cytokine Network Profiling Reveals Synergistic Inflammatory Clusters Associated with PASI Severity in Psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/integrated-cytokine-network-profiling-reveals-synergistic-inflammatory-clusters-associated-with-pasi-severity-in-psoriasis-r654/Psoriasis is a chronic immune-mediated disease driven by interacting pro-inflammatory, angiogenic, and regulatory cytokine pathways. While individual cytokines of the IL-23/Th17 and Th1 axes have been widely studied, less is known about how multiple mediators behave collectively in relation to clinical severity. This study evaluated the integrated serum profile of IL-17A, IL-22, TNF-α, VEGF-A, IL-12(p40), and IL-10 in 34 patients with chronic plaque psoriasis and 19 matched healthy controls, and examined their associations with the Psoriasis Area and Severity Index (PASI). Psoriasis patients showed significantly elevated IL-17A, IL-22, TNF-α, VEGF-A, and IL-12(p40), whereas IL-10 displayed inverse pattern. Hierarchical clustering revealed a tightly interconnected pro-inflammatory cytokine network in untreated patients, with IL-17A, IL-22, and TNF-α forming a core synergistic cluster strongly associated with PASI. Systemic therapy reduced PASI and significantly decreased IL-17A, IL-22, IL-12(p40), and VEGF-A, accompanied by partial normalization of cytokine correlations. ROC analysis identified IL-22 and IL-12(p40) as potential biomarkers of treatment response. These findings demonstrate that psoriasis severity reflects coordinated activity across multiple immune pathways. Integrated cytokine profiling offers a more comprehensive understanding of disease biology and may support development of multi-marker tools for monitoring disease activity and guiding personalized therapy.

Weiterlesen

]]>654Fri, 03 Jul 2026 07:03:51 +0000